Arylalkyloxyalkylamines and arylalkylthioalkylamines, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors

Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need arylalkyloxyalkylamine and arylalkylthioalkylamine compounds, including arylmethoxyalkylamines and arylmethylthioalkylamines, such as pyridylmethoxyalkylamines and pyridylmethylthio alkylamines. Exemplary compounds include methyl(3-(3-pyridylmethoxy)propyl)amine, 3-pyridyl(pyrrolidin-2-ylmethoxy)methane, methyl(1-methyl-2-(3-pyridylmethoxy)ethyl)amine, (3-((3-pyridyl)methoxy)propyl)dimethylamine, (2-((5-bromo-3-pyridyl)methoxy)ethyl)methylamine, methyl(2-((5-methoxy-3-pyridyl)methoxy)ethyl)amine, (2-((3-quinolyl)methoxy)ehtyl)methylamine, methyl(2-(pyrimidin-5-ylmethoxy)ethyl)amine, 3-((3-pyridyl)methoxy)quinuclidine, (3-pyridyl)quinuclidin-2-ylmethoxy)methane, (3-pyridyl)(pyrrolidin-2-ylmethylthio)methane and (2-((3-pyridyl)methylthio)ethyl)methylamine.